Inappropriate ADH Syndrome clinical trials
The registry lists 41 studies for Inappropriate ADH Syndrome across more than 10 countries. 3 are recruiting or about to start. 18 of them are mainly about Inappropriate ADH Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-22.
Get an email when these change. Save the Inappropriate ADH Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University Hospital, Basel, Switzerland (9) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Sanofi (4) · Otsuka Pharmaceutical Europe Ltd (3) · Otsuka Pharmaceutical Co., Ltd. (2) · CardioKine Inc. (2) · Insel Gruppe AG, University Hospital Bern (1) · NYU Langone Health (1)
What is being tested here
Drugs under test in Inappropriate ADH Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Urea | 1 | 0 | 4 |
| Tolvaptan | 0 | 4 | 7 |
| Empagliflozin | 0 | 3 | 4 |
| Satavaptan | 0 | 3 | 4 |
| Lixivaptan | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Apr 2027Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis · University Hospital, Basel, Switzerland
- Nov 2027Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction · University of Turin, Italy
Who these studies take
Of the 3 Inappropriate ADH Syndrome studies recruiting now, 2 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 41 studies, recruiting or not: 7% stop at 75 or younger and 7% at 65; 17% take children; 0% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 41 of 41. search them.
- Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid RestrictionRecruitingNCT07528365Not applicable1 country
- Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate AntidiuresisRecruitingNCT06821802Not applicable1 country
- Low-dose Tolvaptan for Inpatient Hyponatraemia.RecruitingNCT061711001 country
- Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic HyponatremiaCompletedNCT04447911Phase 43 countries
- Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00201994Phase 31 country
- "SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00072683Phase 31 country
- Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADHActive, not recruitingNCT047901751 country
- Urea Therapy for Hyponatremia in Subarachnoid HemorrhageActive, not recruitingNCT04552873Not applicable1 country
- Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIADCompletedNCT06277336Not applicable1 country
- Asymptomatic Bacteriuria, Hyponatremia and Geri-atric SyndromeCompletedNCT05055856Not applicable1 country
- Urea for Chronic HyponatremiaTerminatedNCT04588207Phase 21 country
- Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIADCompletedNCT04987385Not applicable1 country
- Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic HyponatremiaCompletedNCT047449871 country
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx StudyCompletedNCT03202667Phase 2/31 country
- SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric PatientsCompletedNCT03924674Not applicable1 country
- A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADHCompletedNCT03048747Phase 31 country
- Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference StudyStatus unknownNCT04409626
- Water Load Test Value for HyponatremiaCompletedNCT042564991 country
- Tolvaptan Versus Fluid Restriction in SIADHCompletedNCT04119206
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND StudyCompletedNCT02874807Phase 2/31 country
- Fractional Urate Excretion in Nonedematous HyponatremiaWithdrawnNCT01425125Not applicable1 country
- Tolvaptan for Patients With Acute Neurological InjuriesTerminatedNCT02545114Not applicable1 country
- An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in SpainCompletedNCT025488451 country
- An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in ItalyCompletedNCT025730771 country
- An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADHCompletedNCT025451012 countries
- Tolvaptan for In-hospital HyponatremiaTerminatedNCT01386372Phase 21 country
- Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyCompletedNCT02729766Phase 2/31 country
- A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional HyponatremiaTerminatedNCT00728091Phase 31 country
- A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)CompletedNCT02009878Phase 1/27 countries
- Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional HyponatremiaTerminatedNCT01227512Phase 31 country
- Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water HomeostasisCompletedNCT014656721 country
- Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical PracticeStatus unknownNCT012286827 countries
- Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain InjuryCompletedNCT013139751 country
- The Clinical and Laboratory Characteristics of Recurrent Drug- Related HyponatremiaStatus unknownNCT015091701 country
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic HyponatremiaCompletedNCT00876798Phase 38 countries
- International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430CompletedNCT010568481 country
- Subclassification of the Syndrome of Inappropriate ADH SecretionCompletedNCT013416651 country
- Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionCompletedNCT00264914Phase 311 countries
- Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionCompletedNCT00264927Phase 311 countries
- The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)CompletedNCT003909621 country
- Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionCompletedNCT00032734Phase 24 countries